Inhibitor Therapeutics (INTI) Other Accumulated Expenses (2013 - 2022)
Inhibitor Therapeutics (INTI) recorded Other Accumulated Expenses of $65,000 in Q3 2022, up 97.0% from $33,000 a year earlier and unchanged from the prior quarter.
Powered by 
Analysis
Inhibitor Therapeutics (INTI) Other Accumulated Expenses (2013 - 2022) Analysis & Trends
At the end of FY2021, Inhibitor Therapeutics reported Other Accumulated Expenses of $14,965, down 40.4% from FY2020.
- Annual Other Accumulated Expenses has a five-year compound annual growth rate of 7.7% (FY2016 to FY2021).
- Across earlier years, Other Accumulated Expenses came in at $25,124 in FY2020 (+75.2%), $14,339 in FY2019 (-93.4%), $215,876 in FY2018 (+224.5%) and $66,533 in FY2017 (+545.5%).
- Quarterly Other Accumulated Expenses has ranged from $9,310 in Q1 2021 to $215,876 in Q4 2018 over the past five years.
- On a year-over-year basis, Other Accumulated Expenses has increased for three consecutive quarters, with growth averaging 91.1% over the last eight quarters.
- Peak year-over-year performance for Other Accumulated Expenses in the last five years was growth of 743.0% in Q2 2020, against a decline of 93.4% in Q4 2019 at the low end.
- Per Business Quant, the preceding three quarters came in at $65,000 (Q2 2022), $57,000 (Q1 2022) and $14,965 (Q4 2021).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn |
| 10 | Inhibitor Therapeutics | 17.38 Mn | 17.38 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2022 | 65,000.00 |
| Jun 30, 2022 | 65,000.00 |
| Mar 31, 2022 | 57,000.00 |
| Dec 31, 2021 | 14,965.00 |
| Sep 30, 2021 | 33,000.00 |
| Jun 30, 2021 | 15,500.00 |
| Mar 31, 2021 | 9,310.00 |
| Dec 31, 2020 | 25,124.00 |
| Sep 30, 2020 | 133,465.00 |
| Jun 30, 2020 | 86,344.00 |
| Mar 31, 2020 | 40,975.00 |
| Dec 31, 2019 | 14,339.00 |
| Sep 30, 2019 | 22,533.00 |
| Jun 30, 2019 | 10,242.00 |
| Mar 31, 2019 | 30,353.00 |
| Dec 31, 2018 | 215,876.00 |
| Sep 30, 2018 | 171,545.00 |
| Jun 30, 2018 | 79,145.00 |
| Mar 31, 2018 | 44,442.00 |
| Dec 31, 2017 | 66,533.00 |
API Access
Inhibitor Therapeutics Other Accumulated Expenses API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=other-accumulated-expenses&ticker=INTI&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "other-accumulated-expenses", "ticker": "INTI", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=other-accumulated-expenses&ticker=INTI&period=max&api_key=YOUR_API_KEY");
const data = await res.json();